Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38275| Title: | Chemoimmunotherapy may not be dead yet in chronic lymphocytic leukemia, but fludarabine plus cyclophosphamide plus rituximab is potentially facing life support. | Authors: | Hawkes E.A.;Opat S. | Institution: | (Opat) Monash Health, Clayton, Australia (Opat, Hawkes) Monash University, Melbourne, Australia (Hawkes) Austin Health, Heidelberg, Australia (Hawkes) Eastern Health, Box Hill, Australia | Issue Date: | 9-Jan-2018 | Copyright year: | 2017 | Publisher: | American Society of Clinical Oncology (E-mail: jcoservice@asco.org) | Place of publication: | United States | Publication information: | Journal of Clinical Oncology. 35 (36) (pp 4093-4094), 2017. Date of Publication: 20 Dec 2017. | Journal: | Journal of Clinical Oncology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1200/JCO.2017.75.4721 | PubMed URL: | 29099632 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29099632] | ISSN: | 0732-183X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/38275 | Type: | Letter | Type of Clinical Study or Trial: | Opinion, perspective or news |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.